ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1517

Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain

Nelly Ziade1, Avin Maroof2, Antonella Abi Najm1, Torsten Witte3 and Xenofon Baraliakos4, 1Saint-Joseph University, Beirut, Lebanon, 2Rizgary Teaching Hospital - Erbil, Erbil, Iraq, 3MH-Hannover, Hannover, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

Meeting: ACR Convergence 2022

Keywords: Biomarkers, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with axial spondyloarthritis (axSpA) are diagnosed late, partially due to the absence of a reliable biomarker. The diagnostic value of the anti-CD74 antibodies is controverted and the heterogeneity in previous study results may be due to the differences in study populations. In this prospective study, we tested the diagnostic properties of IgA, IgG, and IgG4 anti-CD74 antibodies for axSpA in patients referred for suspicious chronic low back pain (LBP) in Iraq and Lebanon, where the HLA-B27 prevalence is known to be relatively low.

Methods: This is a prospective, multicentric study including adult patients aged less than 45 years and presenting with a history of more than 3 months of “suspicious” LBP which needed a referral to the rheumatologist. Sera of LBP patients and healthy blood donors (HBD) were analyzed for IgA, IgG, and IgG4 by ELISA. Comparison between groups was performed with the Mann-Whitney U test. For the diagnostic properties of anti-CD74 antibodies, ROC curves were calculated to identify the local threshold of positivity. The diagnostic properties of the anti-CD74 antibodies were calculated (sensitivity, specificity, positive predictive value, negative predictive value, and positive likelihood ratio (LR+)).

Results: The sera of 116 patients (52 axSpa and 64 LBP controls) and 121 HBD were analyzed. Patients’ characteristics are reported in Table 1: more males, inflammatory back pain, HLA-B27 (62.7% versus 1%), high CRP, MRI sacroiliitis, and syndesmophytes were found in axSpA patients compared to LBP controls. IgA titers were significantly higher in axSpA patients compared to LBP controls (p=0.043); IgG and IgG4 titers were only numerically higher (Table 2). There was no statistically significant difference in titers between LBP controls and HBD. In the ROC analysis, IgG4 and IgA anti-CD74 showed the best diagnostic properties for axSpA (AUC 0.643 and 642, respectively). Using the ROC curve-identified cut-off value, positive values of IgA were found in 56% of axSpA and 25% of LBP (p< 0.001), of IgG in 81% of axSpA and 64% of LBP (p=0.073) and of IgG4 in 56% of axSpA and 30% of LBP (p=0.005). The LR+ was highest for IgA (2.23) followed by IgG4 (1.88) and IgG (1.25). As a comparator, the LR+ of HLA-B27 was 37.65 (Table 3).

Conclusion: In patients referred for a suspicious chronic LBP to the rheumatologists, IgA anti-CD74 were significantly associated with the final diagnosis of axSpA. However, the LR+ was modest, particularly in comparison with HLA-B27, which may be probably related to the nature of the comparator arm of suspicious LBP.

Supporting image 1

Table 1. Patients’ Characteristics

Supporting image 2

Table 2. Anti-CD74 titers (means, [SD] and HLA-B27 status in patients and donors

Supporting image 3

Table 3. Diagnostic properties of the anti-CD74 antibodies and HLA-B27 for axSpA


Disclosures: N. Ziade, Pfizer, Roche, AbbVie/Abbott, Eli Lilly, Boehringer-Ingelheim, Janssen; A. Maroof, None; A. Abi Najm, None; T. Witte, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, UCB, Galapagos; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi.

To cite this abstract in AMA style:

Ziade N, Maroof A, Abi Najm A, Witte T, Baraliakos X. Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/value-of-the-anti-cd74-antibodies-for-the-diagnosis-of-axial-spondyloarthritis-results-of-a-prospective-study-in-patients-with-suspicious-low-back-pain/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-the-anti-cd74-antibodies-for-the-diagnosis-of-axial-spondyloarthritis-results-of-a-prospective-study-in-patients-with-suspicious-low-back-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology